Bettersone Oint indications
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous
Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
The intra-articular or soft tissue administration of Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
The intralesional administration of Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum.
Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia
Bettersone Oint description
Each gram of Bettersone Oint cream/ointment contains Betamethasone (Bettersone Oint) dipropionate 640 mcg equivalent to Betamethasone (Bettersone Oint) 500 mcg and Gentamicin (Bettersone Oint) sulfate equivalent to Gentamicin (Bettersone Oint) base 1 mg.
Bettersone Oint cream is an oil-in-water emulsion. It contains mineral oil, white petrolatum and cetostearyl alcohol for its oil phase in emulsion base and chlorocresol as preservative.
Bettersone Oint ointment contains white petrolatum as its excipient.
Bettersone Oint dosage
A thin film of Bettersone Oint should be applied to cover completely the affected area twice daily, in the morning and at night.
Frequency of application should be determined by the physician according to the severity of the condition. For some patients, adequate maintenance therapy may be achieved with less frequent application.
Duration of Treatment: Duration of therapy varies depending upon the extent and location of disease and patient response. However, if clinical improvement is not achieved by 3-4 weeks, diagnosis should be reviewed.
Bettersone Oint interactions
Concurrent use of Phenobarbital, Phenytoin, rifampin or ephedrine may enhance the metabolism of corticosteroids, reducing their therapeutic effects.
Patients receiving both a corticosteroid an estrogen should be observed for excessive corticosteroid effects.
Concurrent use of corticosteroids with potassium-depleting diuretics may enhance
Hypokalemia with cardiac glycosides may enhance the possibility of arrhythmias or digitalis toxicity associated with hypokalemia. Corticosteroids may enhance the potassium depletion caused by amphotericin B. In all patients taking any of these drug therapy combinations, serum electrolyte determinations, particularly potassium levels should be monitored closely.
Concurrent use of corticosteroids with coumarin-type anticoagulants may increase or decrease the anticoagulant effects possibly requiring adjustment in dosage.
Combined effects of non-steroidal anti-inflammatory drugs or alcohol with glucocorticosteroids may result in an increased occurrence or increased severity of gastrointestinal ulceration.
Corticosteroids may decrease blood salicylate concentrations. Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Dosage adjustments of an antidiabetic drug may be necessary when corticosteroids are given to diabetics.
Concomitant glucocorticosteroid therapy may inhibit the response to somatotropin.
Laboratory test interactions: corticosteroids may affect the nitroblue tetrazolium test for bacterial infection and produce false negative results.
Bettersone Oint side effects
Adverse reactions to Bettersone Oint cream or ointment therapy have been reported very rarely and include hypersensitivity and skin discoloration.
Treatment with Gentamicin (Bettersone Oint) has produced transient irritation (erythema and pruritus) that usually did not require discontinuance of treatment.
Reported adverse reactions with the use of topical corticosteroids, especially under occlusive dressings, include: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Bettersone Oint contraindications
History of sensitivity reactions to Betamethasone (Bettersone Oint), Gentamicin (Bettersone Oint) or to any of the components of Bettersone Oint.
Topical corticosteroids are contraindicated in vaccinia, varicella and tuberculosis of the skin.
Active ingredient matches for Bettersone Oint:
Betamethasone/gentamicin in Taiwan.
Unit description / dosage (Manufacturer) | Price, USD |
Bettersone Oint 1 g | |
Bettersone Oint 5 g | |
Bettersone Oint 10 g | |
Bettersone Oint 15 g | |
Bettersone Oint 450 g | |
List of Bettersone Oint substitutes (brand and generic names): | |
Bettersone (Taiwan) | |
BG | |
BG 0.064%/0.1% CREAM 1 tube / 15 GM cream each (Geno Pharmaceuticals Ltd) | $ 0.24 |
BG Cream (Geno Pharmaceuticals Ltd) | $ 0.24 |
BV (Greece) | |
Celederm with Gentamicin | |
Cream; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% | |
Celestoderm con Gentalyn (Venezuela) | |
Cream; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Ointment; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Celestoderm cum Garamycin (Finland) | |
Cream; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Ointment; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Celestoderm Gentamicina (Spain) | |
Cream; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Key) | |
Ointment; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Key) | |
Celestoderm met Garamycin (Netherlands) | |
Cream; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Ointment; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Celestoderm-G con Garamicina (Colombia) | |
Celestoderm-V with Garamycin (Georgia, Indonesia, Taiwan) | |
Cream; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Ointment; Topical; Betamethasone Valerate 0.1%; Gentamicin Sulfate 0.1% (Schering-plough) | |
Celestoderm-V with Garamycin 15 g x 1's (Schering-plough) | $ 11.60 |
Celestoderm-V With Garamycin 5 g x 1's (Schering-plough) | $ 4.53 |
Celestoderm-V With Garamycin 10 g x 1's (Schering-plough) | $ 7.23 |
Celestoderm-V with Garamycin 1 g (Schering-plough) | |
Celestoderm-V with Garamycin 5 g (Schering-plough) | |
Celestoderm-V with Garamycin 15 g (Schering-plough) | |
Celestoderm-V with Garamycin 450 g (Schering-plough) | |
Celeston Valerat med Gentamicin (Sweden) | |
Celestone VG (Australia) | |
Celestone-G (South Korea) | |
Corticol 3 (Colombia) | |
Crinex Gen (Paraguay) | |
Debion-VG (Japan) | |
Dermabiolene (Italy) | |
Dermaca (Taiwan) | |
Dermaca 1 g | |
Dermaca 5 g | |
Dermaca 10 g | |
Dermaca 15 g | |
Dermaca 20 g | |
Dermal G (Hong Kong) | |
Dermal G 450 g | |
Dermizol G (Argentina) | |
Dermosol-G (Japan) | |
Dexalergin NF (Argentina) | |
Dexan G (Japan) | |
Dexan VG 0.12% (Japan) | |
Dexan-VG (Japan) | |
See 346 substitutes for Bettersone Oint |
References
- DailyMed. "GENTAMICIN SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Bettersone Oint are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Bettersone Oint. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Bettersone Oint before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 2 weeks and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Bettersone Oint. To get the time effectiveness of using Bettersone Oint drug by other patients, please click here.
Users | % | ||
---|---|---|---|
2 weeks | 1 | 100.0% |
2 consumers reported age
Users | % | ||
---|---|---|---|
16-29 | 1 | 50.0% | |
1-5 | 1 | 50.0% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology